Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad .
Myriad Genetics, Inc.February 12, 2021 GMT
SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.
To embed, copy and paste the code into your website or blog:
For more than a decade, this blog has covered the topic of patentable subject matter. Over the years, we’ve addressed various issues regarding business methods, abstract ideas and other various topics. The “laws of nature” exception has presented itself from time to time, but never before have we seen as dramatic a juxtaposition of two remarkably different cases in this area that both call for the same end result. Among these two cases include: (1) a petition for certiorari submitted by automotive parts manufacturer American Axle on December 28, 2020; and (2) another petition submitted by prenatal testing provider Ariosa Diagnostics on December 30, 2020.
Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan Font : A-A+
from Treatment with Lynparza
More Than 20,000 Patients in Japan Now Qualify for Genetic Testing
SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis
® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japans Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect.
Font : A-A+
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japans Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. Myriads myChoice test is the only one of its kind to be approved for reimbursement in Japan, said Nicole Lambert, president of Myriad Genetic Laboratories. This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.